Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Verisante Technology Inc. V.VRS


Primary Symbol: V.VER.H

Verisante Technology Inc is a Canada based medical device company. It is engaged in commercializing medical systems for the early detection of cancer. The products of the company are Verisante Aura which is for skin cancer detection and Verisante Core which is for lung, colon and cervical cancer detection. It utilizes a cancer detection platform while the operating software and probe technology. The group generates revenue from the sale and renting of its medical devices.


TSXV:VER.H - Post by User

Bullboard Posts
Comment by IronMan07on Oct 20, 2011 10:27am
228 Views
Post# 19166405

RE: New Zacks' Report

RE: New Zacks' Report
Content Provided by Zacks.com
Analyst Blog
Aura Approved in Canada!
October 20, 2011 | Comments: 0
Recommended this article (2)
Aura Approved in Canada!
Brian Marckx, CFA
Health Canada Approval
This morning (10/19/2011) Verisante Technology (V.VRS - Analyst Report, VRSEF) announced that they received marketing approval from Health Canada to market Aura. This marks a major milestone for Verisante and is a testament to the company's ability to get Aura commercialized.
Verisante will now begin preparations for the roll-out in Canada. CE Mark for approval to sell Aura in Europe and Australia is next in line - which could come by the current year-end. As we've noted in the past, the initial roll-out will be a progressive process and, as a result, we model only limited revenue through the end of 2012. By that time, Verisante's distribution and production should be in full-swing and revenue could begin to ramp much faster.
Financial Model
We have made no changes to our model as a result of today's announcement as we had been anticipating the news. We also have not adjusted our price target (remains at $2.60/share), although we feel Canadian regulatory approval reduces downside risk in the share price and provides further support that the stock trades cheaper than warranted. While the stock is up over 125% since we initiated coverage of Verisante in February, we think it could still triple from today's price (
.88) over the course of the next six months.
To view our most recent research reports and subscribe to our daily morning email alert, visit https://scr.zacks.com/. Please email scr@zacks.com with VRS.V as the subject to request a free copy of the full research report.
Follow Zacks Small Cap Research on Twitter at Twitter.com/ZacksSmallCap
Bullboard Posts